Susan E. Ward, PhD

HEAD OF CLINICAL OPERATIONS
Dr. Susan Ward brings significant experience in pharmaceutical clinical development gained at Pfizer, Biogen, and Roche. She has an established track record in the design, leadership, and execution of innovative, cross-disciplinary clinical development programs.
Dr. Ward joins Cell-Gene company from Pfizer, where she was the head of early development clinical trial operations. She began at Pfizer as a clinician in Quantitative Medicine, leading human biology and exploratory research collaborations in biomarker, imaging, and mobile devices. At Biogen, she was a Senior Director and Clinical Program Lead in Translational and Experimental Medicine, where she developed exploratory studies to further research strategy across therapeutic indications in neurology.
Dr. Ward was a clinical consultant in neuroscience at Roche and held positions of increasing responsibility at both biotechnology and pharmaceutical companies, including OvaScience, EnVivo, and Sepracor. She also held the role of Vice President, Global Clinical Affairs at Clinquest, a contract research organization.
She earned a PhD in Behavioral Neuroscience from the Boston University School of Medicine in 2001, while working as a researcher and a Postdoctoral Training Fellow at the Harold Goodglass Aphasia Research Center from 1993 to 2002. She received a BA in Cognitive Science and Psychology from the University of Rochester.
Scroll to Top

Hi
Here you can see some frequently asked questions or contact us!

What passage are your cells?

Our human mesenchymal stem/stromal cells (hMSCs) are provided at a population doubling level (PDL) of 8-10 post-mononuclear isolation (Bone Marrow; Equivalent Passage 2) or 14-18 post-isolation from the perivascular region of Wharton’s Jelly (Umbilical Cord; Equivalent Passage 3). Due to variabilities of seeding and harvest densities we characterize our MSC “True Age” in terms of their PDL.

How often should I feed your cells?

A: There is no need to feed cells between passages. Our media is engineered to be a batch culture media, where no media exchange or feed is necessary when following our suggested protocols.

Are your vials sold from pooled donors?

No, we do not pool donors at any time during our production. Master Cell Banks (MCBs) are created from each donor source. Working Cell Banks (WCBs) are produced from our MCBs for general product sales.

What characterization do you provide for your hMSCs?

We characterize our hMSCs by following ISCT criteria: cell identity (surface marker expression), functional potency (angiogenic cytokine and IDO secretion), and trilineage differentiation (adipo-, osteo-, and chondrogenesis). This information is provided to allow customers to choose the optimal hMSC tissue type and donor for their specific application or target indication.